541 related articles for article (PubMed ID: 12907635)
1. Inactivation of BHD in sporadic renal tumors.
Khoo SK; Kahnoski K; Sugimura J; Petillo D; Chen J; Shockley K; Ludlow J; Knapp R; Giraud S; Richard S; Nordenskjöld M; Teh BT
Cancer Res; 2003 Aug; 63(15):4583-7. PubMed ID: 12907635
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
3. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
Huo L; Sugimura J; Tretiakova MS; Patton KT; Gupta R; Popov B; Laskin WB; Yeldandi A; Teh BT; Yang XJ
Hum Pathol; 2005 Mar; 36(3):262-8. PubMed ID: 15791570
[TBL] [Abstract][Full Text] [Related]
4. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
[TBL] [Abstract][Full Text] [Related]
5. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
8. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.
Vocke CD; Yang Y; Pavlovich CP; Schmidt LS; Nickerson ML; Torres-Cabala CA; Merino MJ; Walther MM; Zbar B; Linehan WM
J Natl Cancer Inst; 2005 Jun; 97(12):931-5. PubMed ID: 15956655
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer.
da Silva NF; Gentle D; Hesson LB; Morton DG; Latif F; Maher ER
J Med Genet; 2003 Nov; 40(11):820-4. PubMed ID: 14627671
[TBL] [Abstract][Full Text] [Related]
10. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
[TBL] [Abstract][Full Text] [Related]
11. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens.
Zhuang Z; Gnarra JR; Dudley CF; Zbar B; Linehan WM; Lubensky IA
Mod Pathol; 1996 Aug; 9(8):838-42. PubMed ID: 8871925
[TBL] [Abstract][Full Text] [Related]
12. Fluorescent and chromogenic in situ hybridization of CEN17q as a potent useful diagnostic marker for Birt-Hogg-Dubé syndrome-associated chromophobe renal cell carcinomas.
Kato I; Iribe Y; Nagashima Y; Kuroda N; Tanaka R; Nakatani Y; Hasumi H; Yao M; Furuya M
Hum Pathol; 2016 Jun; 52():74-82. PubMed ID: 26980015
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas.
Parry L; Maynard JH; Patel A; Clifford SC; Morrissey C; Maher ER; Cheadle JP; Sampson JR
Br J Cancer; 2001 Oct; 85(8):1226-30. PubMed ID: 11710839
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma.
Pan CC; Chen PC; Chiang H
Am J Clin Pathol; 2004 Jun; 121(6):878-83. PubMed ID: 15198361
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite allelotyping differentiates chromophobe renal cell carcinomas from renal oncocytomas and identifies new genetic changes.
Nagy A; Buzogany I; Kovacs G
Histopathology; 2004 Jun; 44(6):542-6. PubMed ID: 15186268
[TBL] [Abstract][Full Text] [Related]
17. S100A1 and KIT gene expressions in common subtypes of renal tumours.
Li G; Gentil-Perret A; Lambert C; Genin C; Tostain J
Eur J Surg Oncol; 2005 Apr; 31(3):299-303. PubMed ID: 15780567
[TBL] [Abstract][Full Text] [Related]
18. Novel intronic germline FLCN gene mutation in a patient with multiple ipsilateral renal neoplasms.
Gatalica Z; Lilleberg SL; Vranic S; Eyzaguirre E; Orihuela E; Velagaleti G
Hum Pathol; 2009 Dec; 40(12):1813-9. PubMed ID: 19733897
[TBL] [Abstract][Full Text] [Related]
19. Expression of vitamin D3 receptor in kidney tumors.
Liu W; Tretiakova M; Kong J; Turkyilmaz M; Li YC; Krausz T
Hum Pathol; 2006 Oct; 37(10):1268-78. PubMed ID: 16949927
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
Chen J; Futami K; Petillo D; Peng J; Wang P; Knol J; Li Y; Khoo SK; Huang D; Qian CN; Zhao P; Dykema K; Zhang R; Cao B; Yang XJ; Furge K; Williams BO; Teh BT
PLoS One; 2008; 3(10):e3581. PubMed ID: 18974783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
